INmune Bio INMB Stock News

INmune Bio Inc (NASDAQ: INMB) is making its way up in the market early on today, and for good reason. The company reported overwhelmingly positive data from a Phase 1 clinical data. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

INMB Reports Positive Clinical Data

In a press release issued early this morning, INmune Bio reported positive preliminary data from a Phase 1 clinical trial. The data was provided during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston.

The data provided came from INB03, a treatment that is currently under developed as part of a combination immunotherapy with the goal of reversing resistance to treatment. In the trial, patients with advanced solid tumors are receiving escalating doses of INB03.

In the release, INMB said that 11 of 12 patients have been enrolled to date into one of three dosing cohorts. All patients included have received multiple prior lines of therapy for varrying forms of solid tumors, all lacking an adequate response to these therapies.

Patients received INB03 once per week via injection. The comapny then followed safety, pharmacokinetics and inflammatory biomarkers in all patients.

In the release, INMB said that preliminary data from patients treated in the first two cohorts are available. These include two male and four female patients at an average age of 63 years old.

INB93 was provided over a course of 74 days on average. To date, no drug-related serious adverse events were reported and the treatment is proving to be well tolerated. Moreover, target levels were achieved in three of three patients in the 1.0 mg/kg group. Moreover, inflammatory cytokine IL6 was decreased by more than 50% in half of the patients.

In a statement, RJ Tesi, MD, CEO and CMO at INMB, had the following to offer:

The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03. All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.

This News Is HUGE!

The news released by INmune Bio proved to be incredibly positive. After all, while we are in early stages here, the data suggests that not only is INB03 safe and well tolerated, it is proving to be effective.

Should data continue down these lines through the completion of this study and in future studies, the company could have a blockbuster drug on its hand. Lets not forget the fact that the solid tumor market is worth tens of billions of dollars annually.

Considering the fact that INMB trades with a market cap of around $100 million, the market opportunity here is substantial. All in all, the company wouldn’t need to tackle any more than a very small percentage of this market to return serious value to investors!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time alerts!

Subscribe Today!

* indicates required



CNA Finance, parent company to Alpha Stock News, has a monetary relationship with INMB. Read the full disclosure here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.